With facilities and personnel in various locations on both coasts, the wound healing work in Microcures is based on the work of David Sharp, Ph.D., the firm's founder and chief scientific officer, and an expert on cell movement, Microcures has established a first-of-its-kind cell motility modulation platform that represents an innovative approach to tissue repair and disease treatment. Targeting the microtubule cytoskeleton to change the activity of microtubule regulatory proteins that control cell growth, and motility, Microcures Inc is developing nanoparticle therapeutics to enhance tissue regeneration and repair. The firm offers enhancer technology as well as inhibitor technology to promote the cellular healing process. The enhancer technology is designed to heal wounds, regenerate axon, and assist with myocardial infarction by regenerating vessels. On the other end, inhibitor technology limits fibrosis in tissues and organs, as well as suppress the movement of cancer cells.